A Prospective Study of Comparing Multi-Gene Biomarker Chip and Serum Carcinoembryonic Antigen in the Postoperative Surveillance for Patients with Stage I-III Colorectal CancerReportar como inadecuado




A Prospective Study of Comparing Multi-Gene Biomarker Chip and Serum Carcinoembryonic Antigen in the Postoperative Surveillance for Patients with Stage I-III Colorectal Cancer - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

Background

Circulating biomarkers can predict clinical outcomes in colorectal cancer patients. The aim of the study was to evaluate the feasibility of our multigene biomarker chip for detecting circulating tumor cells for postoperative surveillance of stage I–III colorectal cancer patients.

Materials and Methods

In total, 298 stage I–III colorectal cancer patients were analyzed after curative resection between June 2010 and October 2014. During each follow-up, a postoperative surveillance strategy, including ESMO Guidelines Working Group recommendations and the biochip, was used.

Results

After a 28.4-month median follow-up, 48 16.1% patients had postoperative relapse. Univariate analysis revealed that the postoperative relapse risk factors were rectal tumor, perineural invasion, elevated preoperative and postoperative serum carcinoembryonic antigen levels, and positive biochip results all P < 0.05. Multivariate analyses revealed that postoperative relapse correlated significantly with elevated postoperative serum carcinoembryonic antigen levels odds ratio = 4.136, P = 0.008 and positive biochip results odds ratio = 66.878, P < 0.001. However, the sensitivity P = 0.003, specificity P = 0.003, positive P = 0.002 and negative P = 0.006 predictive values, and accuracy P < 0.001 of the biochip for predicting postoperative relapse were significantly higher than those of elevated postoperative serum carcinoembryonic antigen levels. Moreover, the median lead time between positive biochip result and postoperative relapse detection was significantly earlier than that between elevated postoperative serum carcinoembryonic antigen level and postoperative relapse detection 10.7 vs. 2.8 months, P < 0.001. Furthermore, positive biochip results correlated strongly with lower disease-free survival and overall survival of colorectal cancer patients both P < 0.001.

Conclusion

Compared with conventional serum carcinoembryonic antigen detection, our multigene chip aided more accurate and earlier prediction of postoperative relapse during stage I–III colorectal cancer patient surveillance. In clinical practice, this biochip may facilitate early postoperative relapse diagnosis in colorectal cancer patients.



Autor: Yu-Tang Chang, Ming-Yii Huang, Yung-Sung Yeh, Ching-Wen Huang, Hsiang-Lin Tsai, Tian-Lu Cheng, Jaw-Yuan Wang

Fuente: http://plos.srce.hr/



DESCARGAR PDF




Documentos relacionados